Problem

Chemical and pharmaceutical process development is often a costly, slow, trial-and-error bottleneck. Teams may need dozens of experiments to identify viable reaction conditions, consuming reagents, instrument time, analytical capacity, and scientists’ time while delaying scale-up and manufacturing readiness. The pain is especially acute when yield, impurity, speed, or robustness must be optimized simultaneously; ReactWise cites a hydrogenation project that reached 97.5% yield and 1% impurity while uncovering a previously overlooked temperature-profile parameter.

The economic proposition is to reduce wasted experimental runs and shorten development timelines. ReactWise says customers have reported process-development acceleration of more than 50%, while its funding announcement claims that historical-data-driven models can cut up to 95% of experimental work and accelerate workflows by as much as 30x. The killer use case is a difficult reaction or process where conventional optimization has stalled and every additional experiment carries meaningful cost or schedule impact.

Product / Service

ReactWise is a cloud-based AI copilot for chemical process optimization. Its Bayesian-optimization engine learns from each experiment, represents uncertainty across the design space, and recommends the next most informative conditions to test. Its MemoryBO transfer-learning system can use prior campaigns and historical data to give a new project an informed starting point, while the platform also offers HTE plate design, solvent selection, and automated kinetic modeling. The intended users are bench and process chemists, engineers, automation scientists, and biotechnologists, with no programming or machine-learning expertise required.

The delivery model combines software, integrations, and optional laboratory services. Teams can upload spreadsheets, connect ELNs or other lab systems, or use an API to connect liquid handlers, PAT instruments, flow-chemistry equipment, and other automated hardware for closed-loop optimization. ReactWise also operates a lab that generates pre-trained datasets and runs experimental campaigns on demand. The benefit is a more practical path from experiment design to interpretable optimization, with fewer runs, lower reagent and analysis costs, faster results, and the possibility of autonomous execution.

Market

ReactWise competes in AI-enabled chemical process development, laboratory informatics, high-throughput experimentation, and the emerging self-driving-laboratory market. Its primary customers are pharmaceutical and fine-chemical R&D teams, with stated expansion into biotech, materials science, cosmetics, agrochemicals, and food and fragrance applications. The competitive set includes legacy statistical design-of-experiments and process-optimization tools such as JMP, as well as newer AI reaction-optimization products such as Chemical.AI’s ChemAIRS. ReactWise’s differentiation is the combination of Bayesian optimization, chemistry-specific descriptors and proprietary data, transfer learning, explainable visualizations, and hardware/ELN integration rather than experiment-selection software alone.

The company shows meaningful early commercial traction rather than looking purely pre-revenue. ReactWise announced $3.4 million in pre-seed funding in March 2025, reported that it was running 12 pilot studies with large pharmaceutical companies, and by June 2026 said that five of the world’s ten largest pharmaceutical companies trusted it. Public materials name or reference customers and users including Pfizer, Pharmaron, Biogen, Amgen, Fraunhofer IMM, and the University of Cambridge; its terms also describe paid user subscriptions. No reliable public audited revenue figure is established in the available evidence, but the combination of pilots, named enterprise users, subscription terms, and repeat pharma adoption indicates an active early commercialization stage.